Protara Therapeutics Capital Expenditures (CapEx) Growth & History (TARA)
Protara Therapeutics's capital expenditures (capex) was $94,000 for fiscal 2025.
View full Protara Therapeutics company overviewProtara Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $94,000 | $31,000 | +49.21% |
| 2024 | 2024-12-31 | $63,000 | $18,000 | +40.00% |
| 2023 | 2023-12-31 | $45,000 | −$75,000 | −62.50% |
| 2022 | 2022-12-31 | $120,000 | −$476,000 | −79.87% |
| 2021 | 2021-12-31 | $596,000 | −$288,000 | −32.58% |
| 2020 | 2020-12-31 | $884,000 | $409,000 | +86.11% |
| 2019 | 2019-12-31 | $475,000 | $356,000 | +299.16% |
| 2018 | 2018-12-31 | $119,000 | $84,000 | +240.00% |
| 2017 | 2017-12-31 | $35,000 | −$236,000 | −87.08% |
| 2016 | 2016-12-31 | $271,000 | $73,000 | +36.87% |
| 2015 | 2015-12-31 | $198,000 | $147,000 | +288.24% |
| 2014 | 2014-12-31 | $51,000 | $41,000 | +410.00% |
| 2013 | 2013-12-31 | $10,000 | −$57,000 | −85.07% |
| 2012 | 2012-12-31 | $67,000 | — | — |
Protara Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $24,000 | — | — |
| Q3 2025 | 2025-09-30 | $4,000 | −$4,000 | −50.00% |
| Q2 2025 | 2025-06-30 | $22,000 | — | — |
| Q1 2025 | 2025-03-31 | $44,000 | — | — |
| Q3 2024 | 2024-09-30 | $8,000 | −$29,000 | −78.38% |
| Q4 2023 | 2023-12-31 | $0 | −$6,000 | — |
| Q3 2023 | 2023-09-30 | $37,000 | −$46,000 | −55.42% |
| Q2 2023 | 2023-06-30 | $2,000 | −$18,000 | −90.00% |
| Q1 2023 | 2023-03-31 | $6,000 | −$5,000 | −45.45% |
| Q4 2022 | 2022-12-31 | $6,000 | −$38,000 | −86.36% |
| Q3 2022 | 2022-09-30 | $83,000 | $19,000 | +29.69% |
| Q2 2022 | 2022-06-30 | $20,000 | −$306,000 | −93.87% |
| Q1 2022 | 2022-03-31 | $11,000 | −$279,000 | −96.21% |
| Q4 2021 | 2021-12-31 | $44,000 | −$467,000 | −91.39% |
| Q3 2021 | 2021-09-30 | $64,000 | −$68,000 | −51.52% |
| Q2 2021 | 2021-06-30 | $326,000 | $320,000 | +5333.33% |
| Q1 2021 | 2021-03-31 | $290,000 | $43,000 | +17.41% |
| Q4 2020 | 2020-12-31 | $511,000 | $465,138 | +1014.21% |
| Q3 2020 | 2020-09-30 | $132,000 | −$193,400 | −59.43% |
| Q2 2020 | 2020-06-30 | $6,000 | −$70,625 | −92.17% |
| Q1 2020 | 2020-03-31 | $247,000 | $219,887 | +811.00% |
| Q4 2019 | 2019-12-31 | $45,862 | −$49,138 | −51.72% |
| Q3 2019 | 2019-09-30 | $325,400 | $322,400 | +10746.67% |
| Q2 2019 | 2019-06-30 | $76,625 | $64,625 | +538.54% |
| Q1 2019 | 2019-03-31 | $27,113 | $18,113 | +201.26% |
| Q4 2018 | 2018-12-31 | $95,000 | $83,000 | +691.67% |
| Q3 2018 | 2018-09-30 | $3,000 | −$6,000 | −66.67% |
| Q2 2018 | 2018-06-30 | $12,000 | $4,000 | +50.00% |
| Q1 2018 | 2018-03-31 | $9,000 | $3,000 | +50.00% |
| Q4 2017 | 2017-12-31 | $12,000 | $0 | 0.00% |
| Q3 2017 | 2017-09-30 | $9,000 | −$48,000 | −84.21% |
| Q2 2017 | 2017-06-30 | $8,000 | −$186,000 | −95.88% |
| Q1 2017 | 2017-03-31 | $6,000 | −$2,000 | −25.00% |
| Q4 2016 | 2016-12-31 | $12,000 | −$15,000 | −55.56% |
| Q3 2016 | 2016-09-30 | $57,000 | −$78,000 | −57.78% |
| Q2 2016 | 2016-06-30 | $194,000 | $163,000 | +525.81% |
| Q1 2016 | 2016-03-31 | $8,000 | $3,000 | +60.00% |
| Q4 2015 | 2015-12-31 | $27,000 | — | — |
| Q3 2015 | 2015-09-30 | $135,000 | $126,000 | +1400.00% |
| Q2 2015 | 2015-06-30 | $31,000 | — | — |
| Q1 2015 | 2015-03-31 | $5,000 | — | — |
| Q3 2014 | 2014-09-30 | $9,000 | — | — |
Protara Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Protara Therapeutics's capital expenditures (capex) decreased from $884,000 to $94,000, a change of −$790,000. The latest reported quarter, Q4 2025, shows $24,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protara Therapeutics source filings ↗